(2018), Cell Metab 27(3), PubMed 29514064 Statistics from preclinical literature NAD+ (nicotinamide adenine dinucleotide), a key cofactor of redox reactions and substrate for sirtuins, PARP, CD38 , molecular weight 663.43 g/mol (not a peptide, but traditionally included in peptide research collections) Identified by Arthur Harden (Nobel Prize 1929) in 1906 as a coferment Standard experimental intravenous dose in clinical studies: 250750 mg/day for 410 days (Grant 2019, Conlon & Bird 2020) NAD+ levels decline with age by ~50 % in various tissues between ages 30 and 80 (Massudi 2012) Mechanism of supplementation: direct intravenous repletion, or precursors NR (nicotinamide riboside), NMN (nicotinamide mononucleotide) that are converted to NAD+ via NAMPT/NRK enzymes In Conlon & Bird (2020, n=11): NAD+ IV infusion 750 mg/day for 6 days raised plasma NAD+ by ~40 % over baseline NR and NMN are registered in the USA as dietary supplements (NDI status)
Metabolomics in prediabetes and diabetes: a systematic review and meta-analysis
Specific oligonucleotide primers for 3-AR and actin were used, generating PCR products of 234 base pairs and 559 base pairs, respectively
3a, Huh7, Hep3B, and HepG2)
As you age, your natural production of HGH declines
